fludarabine + bortezomib + rituximab

A three-drug, investigational chemoimmunotherapy regimen combining the nucleoside analog fludarabine, the proteasome inhibitor bortezomib, and the anti-CD20 monoclonal antibody rituximab. In a phase I study in relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma, bortezomib was hypothesized to potentiate fludarabine by inhibiting DNA repair; rituximab was added to target CD20-positive B cells. The maximum tolerated schedule identified was fludarabine 25 mg/m2 on days 1–3, bortezomib 1.3 mg/m2 on days 1, 4, 8, 11, and rituximab 375 mg/m2 on day 1 of a 21-day cycle, showing activity with cumulative myelosuppression and neuropathy as key toxicities.

Other names

FBR regimen